Methods: 41 UT resections were identified, 14 with a history of bladder cancer (BC). Whole sections were stained for PD-L1, PD-1, and CD8. PD-L1 IHC was documented in epithelial and lymphohistiocytic compartments {papillary cores (PC) and peritumoral (PT)} in a semi-quantitative manner and H scores calculated (intensity X percentage). A cutoff of ≥1% membranous staining was considered positive. CD8 and PD-1+ lymphocytes were quantified. GraphPad was used for statistical analysis. Results: The frequency of UT PD-L1 expression in various tumor compartments was as follows: 39% epithelial, 25% PC, and 37% PT, with higher frequencies in pT3 tumors (10/15 epithelial; 4/15 PC; 9/15 PT). Twenty-five percent of UT tumors revealed >5% epithelial staining. By linear regression, epithelial PD-L1 expression was associated with squamous differentiation (SqD), tumor size, stage, and degree of tumoral lymphocytic (including PD-1+) infiltration (all P ≤ .05); and by multivariate regression, only SqD was significant (P = .0002). Mean H scores for PD-L1 tended to be higher in tumors with SqD (mean 0.42, SD 0.6, n = 7/16) vs no-SqD (mean 0.09, SD 0.1, n = 9/16). CD8 and PD-1+ tumor infiltration was similar in the squamous vs non-squamous group. No difference in PD-L1 expression was noted in patients with UT only as compared to those with both UT and BC. Conclusions: In upper tract tumors, PD-L1 is strongly associated with squamous differentiation regardless of other clinicopathologic features. Tumors with squamous differentiation have higher PD-L1 H scores when compared to those without squamous differentiation. Larger studies are needed to further assess the significance of PD-L1 expression in upper tract urothelial carcinoma with squamous differentiation.
Introduction: PAX2 and PAX8 transcription factors are known to be expressed by several renal neoplasms, and immunostains for one or both are usually added in their diagnostic panel. Objective: To evaluate the relative diagnostic utility of PAX2 and PAX8. Material and Methods: Biopsy and excision specimens of primary and metastatic renal and urothelial neoplasms with available PAX2 and PAX8 immunostains were retrospectively searched (from January 2010 to March 2017) from three hospitals.
Results: A total of 23 tumor (16 primary, seven metastatic) specimens reporting both PAX8 and PAX2 stains in the diagnostic work-up were identified. Within the primary neoplasms, the overall PAX8 and PAX2 expression was seen in 14 of 16 (87.5%) vs four of 16 (25.0%) tumors with two of two (100%) vs one of two (50%) for renal cell carcinoma (RCC; clear cell and papillary), four of six (66.0%) vs none of six (0.0%) for RCC-chromophobe type, five of five (100.0%) vs two of five (40.0%) for oncocytomas, and two of three (66.6%) vs one of three (33.3%) for adenocarcinoma of bladder. Within the metastatic neoplasms, the overall PAX8 vs PAX2 expression was seen in five of seven (71.4%) vs two of seven (28.6%) tumors with four of four (100.0%) vs two of four (50.0%) for clear cell RCC, and one of one (100.0%) vs none of one (0.0%) for medullary collecting duct carcinoma. Both markers were negative for metastatic urothelial carcinoma (0/2). PAX8 was positive in all the metastatic RCC (5/5; 100%) whereas PAX2 was positive in only two of five (40.0%). Conclusions: Both PAX8 and PAX2 are useful markers for diagnosis of primary and metastatic renal neoplasms of variable histologic types. However, PAX8 appears to be more sensitive in malignant cells with more intense staining. Comparatively, PAX2 delivers limited diagnostic yield.
HPV and p16 in Mesenchymal Tumors and Sarcomatoid Carcinoma of the Head and Neck
Parisa Mansoori, Ariel Frost, Nora Zbieranski, (ASCP) MB, Stacey O'Neill, MD, PhD, Shadi Qasem, MD; Wake Forest School of Medicine, Winston-Salem, NC Introduction: Squamous cell carcinoma (SCC) is the most common malignancy of the head and neck, and the association of human papillomavirus (HPV) infection with oropharyngeal SCC is well established. HPV-positive oropharyngeal SCC is consistently associated with better survival when compared to patients with HPV-negative ones; hence, reflex testing for HPV status is routinely recommended for these tumors. Laboratory methods currently include HPV DNA detection through polymerase chain reaction (PCR) or in situ hybridization (ISH) techniques, or detection of p16 expression by immunohistochemistry (IHC), a surrogate for HPV oncoprotein function. On the other hand, not many studies have evaluated head and neck mesenchymal tumors for HPV. Our goal is to evaluate the head and neck mesenchymal tumors and sarcomatoid carcinomas for p16 and HPV in a retrospective study. Material and Method: We identified 50 cases of previously diagnosed sarcomatoid carcinoma and mesenchymal tumors of the head and neck in our archives (21 sarcomatoid carcinoma, 28 mesenchymal tumors, and one poorly differentiated malignant neoplasm). The mesenchymal
